Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Yoo Jin | - |
dc.contributor.author | Kim, Hye Young | - |
dc.contributor.author | Lee, Mi Hwa | - |
dc.contributor.author | Suh, Sung Hwan | - |
dc.contributor.author | Choi, Yongmun | - |
dc.contributor.author | Nam, Tae-gyu | - |
dc.contributor.author | Kwon, Woo Young | - |
dc.contributor.author | Lee, Sang Yeob | - |
dc.contributor.author | Yoo, Young Hyun | - |
dc.date.accessioned | 2021-06-22T11:03:23Z | - |
dc.date.available | 2021-06-22T11:03:23Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2018-12 | - |
dc.identifier.issn | 0026-895X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/4724 | - |
dc.description.abstract | Nonalcoholic fatty liver disease (NAFLD) is an increasingly studied condition that can progress to end-stage liver disease. Although NAFLD was first described in 1980, a complete understanding of the mechanism and causes of this disease is still lacking. Six-transmembrane protein of prostate 2 (STAMP2) plays a role in integrating inflammatory and nutritional signals with metabolism. Our previous study suggested that STAMP2 may be a suitable target for treating NAFLD. In the current study, we performed a focused drug-screening and found that cilostazol could be a potential STAMP2 enhancer. Thus, we examined whether cilostazol alleviates NAFLD through STAMP2. The in vivo and in vitro pharmacological efficacies of cilostazol on STAMP2 expression and lipid accumulation were analyzed in NAFLD mice induced by high-fat diet (HFD) and in HepG2 cell lines treated by oleic acid (OA), respectively. Cilostazol increased the expression of STAMP2 through transcriptional regulation in vivo and in vitro. Cilostazol also dampened the STAMP2 downregulation caused by the HFD and by OA in vivo and in vitro, respectively. Cilostazol activated AMP-activated protein kinase (AMPK) in vivo and in vitro, and AMPK functions upstream of STAMP2, and reversed downregulation of STAMP2 expression through AMPK in the NAFLD model. Cilostazol ameliorates hepatic steatosis by enhancing hepatic STAMP2 expression through AMPK. Enhancing STAMP2 expression with cilostazol represents a potential therapeutic avenue for treatment of NAFLD. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS | - |
dc.title | Cilostazol Improves HFD-Induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression through AMPK | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Nam, Tae-gyu | - |
dc.identifier.doi | 10.1124/mol.118.113217 | - |
dc.identifier.scopusid | 2-s2.0-85056505158 | - |
dc.identifier.wosid | 000454833200009 | - |
dc.identifier.bibliographicCitation | MOLECULAR PHARMACOLOGY, v.94, no.6, pp.1401 - 1411 | - |
dc.relation.isPartOf | MOLECULAR PHARMACOLOGY | - |
dc.citation.title | MOLECULAR PHARMACOLOGY | - |
dc.citation.volume | 94 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1401 | - |
dc.citation.endPage | 1411 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | NONALCOHOLIC FATTY LIVER | - |
dc.subject.keywordPlus | ADIPOSE-TISSUE | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | INSULIN | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | STEATOHEPATITIS | - |
dc.subject.keywordPlus | INFLAMMATION | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordAuthor | NONALCOHOLIC FATTY LIVER | - |
dc.subject.keywordAuthor | ADIPOSE-TISSUE | - |
dc.subject.keywordAuthor | IN-VITRO | - |
dc.subject.keywordAuthor | INSULIN | - |
dc.subject.keywordAuthor | DISEASE | - |
dc.subject.keywordAuthor | STEATOHEPATITIS | - |
dc.subject.keywordAuthor | INFLAMMATION | - |
dc.subject.keywordAuthor | PROTEIN | - |
dc.subject.keywordAuthor | ACTIVATION | - |
dc.subject.keywordAuthor | INHIBITOR | - |
dc.identifier.url | https://molpharm.aspetjournals.org/content/94/6/1401 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.